The UK Medicines and Healthcare products Regulatory Agency (MHRA) has on 3rd May, 2024 approved two new formulations of the medicine cabotegravir (Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection) to help prevent sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35kg who are at an increased risk of infection. Cabotegravir has been authorised as tablets and as a long-acting injection administered every two months.
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship
ViiV to present data for its next generation of ultra long-acting treatments
GSK`s injectable HIV drug shows promise over daily pills
ViiV Healthcare’s latest campaign to drive awareness of its HIV pre-exposure prophylaxis (PrEP) therapies enlists celebrity comedians in the familiar chatting-in-cars format.
ViiV Health announces new packaging option now available in the U.S. for Dovato
ViiV Healthcare receives approval from China’s NMPA for Vocabria
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023